Abiraterone acetate not checked

Johnson & Johnson (Janssen)

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1 trial completes
Trials
16 active
23 in total · 13 in the EU
Targets
 

What this is

How it works
Cytochrome P450 17A1 Inhibitor FDA class
How it’s given
“Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.”In the company’s words, NCT02257736 on ClinicalTrials.gov
Tested for
Prostatic Neoplasms (4 trials), Castration-Resistant Prostatic Cancer, Prostatic Neoplasms, Castration-Resistant, Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Main trialPhase 3
“The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy \[treatment of cancer using drugs\]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland \[gland that makes fluid that aids movement of sperm\]).”In the company’s words, NCT02257736 on ClinicalTrials.gov
Other names
ZYTIGA

Other drugs for Prostatic Neoplasms

All 194 drugs for Prostatic Neoplasms

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials23

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 19 Mar 2018 An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 3Active, not recruiting 8 Oct 2021 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Phase 3Active, not recruiting 7 Jan 2025 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Phase 2Active, not recruiting 31 Aug 2021 A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1Active, not recruiting 27 Jun 2016 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1Active, not recruiting 15 Oct 2021 A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Phase 1Active, not recruiting 31 Dec 2026 ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Phase 1Recruiting 31 Aug 2027 A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 4Completed 31 Dec 2017 A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
Phase 3Completed 31 Mar 2014 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 3Completed 31 Oct 2016 A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Phase 3Completed 22 Apr 2021 A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Phase 2Completed 24 Dec 2013 IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Phase 1Completed 10 May 2014 Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Phase 1Terminated 30 Sep 2022 A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 3Authorised not given Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
Phase 2Authorised not given Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST)
Phase 3Authorised not given B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents
Phase 3Authorised not given EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE)
Phase 3Authorised not given ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer
Phase 4Authorised not given RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC)
Phase 4Authorised not given Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG
Phase 4Authorised not given Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Abiraterone acetate

Following is part of Solo: you see every change to Abiraterone acetate the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in